Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103340 | 0.90 | — | — | |
| SCHEMBL5109455 | 0.87 | DHODH (0.33) | — | |
| SCHEMBL5115255 | 0.84 | HTT (0.36) | RORCKMT2A | |
| SCHEMBL4737882 | 0.82 | RAB9A (0.35) | RAB9ANPC1CNR1CNR2KMT2A | |
| SCHEMBL4963101 | 0.78 | DHODH (0.34) | — | |
| SCHEMBL4964116 | 0.76 | RAB9A (0.36) | RORCRAB9ANPC1RXFP1CNR1 | |
| SCHEMBL4663231 | 0.74 | LIPG (0.39) | RAB9ARXFP1CNR1CNR2TNKS | |
| SCHEMBL4961708 | 0.74 | KDM4E (0.34) | RAB9ANPC1SMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4784972 | 0.72 | NPY5R (0.33) | RAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL4739802 | 0.71 | NPC1 (0.32) | RAB9ANPC1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | RORC 2699/4885RAB9A 2427/4885NPC1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.